Date: 2 December 2021 Your Name: <u>CHEUNG Tan To</u>

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	□ None	Eisai for medical writing
	provision of study materials,		
	medical writing, article processing charges, etc.)  No time limit for this item.		
		Time frame: past	26 months
		Tille Italile. past	
2	Grants or contracts from	☐ None	Eisai for funding support to an investigator-initiated
	any entity (if not indicated		study
	in item #1 above).		
3	Royalties or licenses	⊠ None	
4	Consulting fees	None     Non	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None	BMS for provision of drug to an investigator-initiated study
13	Other financial or non- financial interests	⊠ None	

## Please summarize the above conflict of interest in the following box:

TTC has received research funding from Eisai for medical writing and for funding support to an investigator-initiated study, and study support from BMS for provision of drug to an investigator-initiated study.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2 December 2021

Your Name: Simon Chun-Ho Yu

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
		_	
4	Consulting fees	None	

_			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12		None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

No conflict of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date: 2 December 2021

4

Consulting fees

 $\square$  None

Your Name:Stephen L. Chan					
Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review				N	
and update for 2021					
Ma	anuscript number (if known)	): HBSN-21-405			
	Walluscript Humber (II known). HB3N-21-403				
rel pa to	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>		
to	•	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.		
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
		Name all entities with	Specifications/Comments		
			Specifications/ comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate			
		relationship or indicate none (add rows as	(e.g., if payments were made to you or to your		
		relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)		
1	All support for the present	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding,	relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding, provision of study materials,	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding,	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed)  Time frame: Since the initia  None	(e.g., if payments were made to you or to your institution)  Il planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)  Il planning of the work		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	relationship or indicate none (add rows as needed)  Time frame: Since the initia  None	(e.g., if payments were made to you or to your institution)  Il planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	relationship or indicate none (add rows as needed)  Time frame: Since the initial None  Time frame: past  None  Bayer, MSD, Eisai, Sirtex,	(e.g., if payments were made to you or to your institution)  Il planning of the work		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	relationship or indicate none (add rows as needed)  Time frame: Since the initiate None  Time frame: past	(e.g., if payments were made to you or to your institution)  Il planning of the work  t 36 months		

		Novartis, MSD, Eisai, AstraZeneca, BMS	Advisors
_	December to the control of the		
5	Payment or honoraria for lectures, presentations,	□ None	
	speakers bureaus, manuscript writing or educational events	Bayer; Astra-Zeneca; Eisai; Roche; MSD	honoraria
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role	⊠ None	
	in other board, society,	Zivone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	⊠ None	
	financial interests		

### Please summarize the above conflict of interest in the following box:

Stephen Chan has received research grants from Bayer, MSD, Eisai, Sirtex, and Ipsen, consulting fees from Novartis, MSD, Eisai, AstraZeneca, and Bristol Myers Squibb, and speaking honoraria from Bayer, Astra-Zeneca, Eisai, Roche, and MSD.

Please place an "X" next to the following statement to indicate your agreement:

Date: 22 December 2021 Your Name: Ronnie TP Poon

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5	Payment or honoraria for		
5	lectures, presentations, speakers bureaus,	⊠ None	
	manuscript writing or		
	educational events		
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or	⊠ None	
	pending		
_		_	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	
		_	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	⊠ None	
	financial interests		

# Please summarize the above conflict of interest in the following box:

I declare no conflict of interest pertaining to the work reported in this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2 December 2021

Your Name: Chong-hei Philip Kwok

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial  ☑ None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Е	Payment or honoraria for		
5	lectures, presentations,	⊠ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data Safety Monitoring Board or	⊠ None	
	Advisory Board		
4.0	•		
10	Leadership or fiduciary role	⊠ None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	⊠ None	
	Stock of Stock options	EN INUITE	
12	Receipt of equipment,	⊠ None	
-	materials, drugs, medical	∠ IVUIIC	
	writing, gifts or other		
	services		
13	Other financial or non-	⊠ None	
	financial interests		
Ple	ase summarize the above c	onflict of interest in the fol	lowing box:

Date: 2 December 2021
Your Name:LEE, Ann Shing
Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative revi
and update for 2021
Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Payment or honoraria for	⊠ None	
educational events		
	⊠ None	
testimony		
Support for attending	⊠ None	
meetings and/or travel	Z None	
Patents planned issued or	№	
pending	⊠ None	
Participation on a Data	⊠ None	
•	<b>5</b> 2	
	⊠ None	
committee or advocacy		
Stock of Stock options	⊠ None	
Receipt of equipment,	⊠ None	
services		
Other financial or non- financial interests	⊠ None	
ease summarize the above c	onflict of interest in the following box:	
None.		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial interests  Payment for expert  None  None  None  None  None  None  None  None

Date: 2 December	2021	
Your Name:	Tai Yin Ping	
Manuscript Title:	The Hong Kong Consens	sus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 20	21	
Manuscript number	er (if known): HBSN-21-	405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Payment or honoraria for	⊠ None	
educational events		
	⊠ None	
testimony		
Support for attending	⊠ None	
meetings and/or travel	Z None	
Patents planned issued or	№	
pending	⊠ None	
Participation on a Data	⊠ None	
•	<b>5</b> 2	
	⊠ None	
committee or advocacy		
Stock of Stock options	⊠ None	
Receipt of equipment,	⊠ None	
services		
Other financial or non- financial interests	⊠ None	
ease summarize the above c	onflict of interest in the following box:	
None.		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial interests  Payment for expert  None  None  None  None  None  None  None  None

Date: 2 Decen	nber 2021
Your Name: _	_Tam Tak Lap Derek
Manuscript Ti	tle: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update fo	r 2021
Manuscript nu	umber (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
manuscript writing or educational events  6  Payment for expert testimony  7  Support for attending meetings and/or travel  8  Patents planned, issued or pending  9  Participation on a Data Safety Monitoring Board or Advisory Board	
educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board	
testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
9 Participation on a Data Safety Monitoring Board or Advisory Board  None	
Safety Monitoring Board or Advisory Board	
Safety Monitoring Board or Advisory Board	
· ·	
10   Leadership or fiduciary role	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options None	
12 Receipt of equipment, 🗵 None	
materials, drugs, medical writing, gifts or other	
services	
13 Other financial or non-	
financial interests	
Please summarize the above conflict of interest in the following box:	

Date: 2 December 2021
Your Name: Chin-Cheung Cheung
Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 2021
Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Payment or honoraria for	⊠ None	
educational events		
	⊠ None	
testimony		
Support for attending	⊠ None	
meetings and/or travel	Z None	
Patents planned issued or	№	
pending	⊠ None	
Participation on a Data	⊠ None	
•	<b>5</b> 2	
	⊠ None	
committee or advocacy		
Stock of Stock options	⊠ None	
Receipt of equipment,	⊠ None	
services		
Other financial or non- financial interests	⊠ None	
ease summarize the above c	onflict of interest in the following box:	
None.		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial interests  Payment for expert  None  None  None  None  None  None  None  None

Date: 2 Decembe	r 2021
Your Name:	Tak Wing LAI
<b>Manuscript Title:</b>	The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 20	)21
Manuscript numb	per (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial  None	pranning of the work
1	manuscript (e.g., funding,	None	
	provision of study materials, medical writing, article processing charges, etc.)		
	No time limit for this item.		
		<b>-</b> : .	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	⊠ None	
	in item #1 above).		
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Payment or honoraria for	⊠ None	
educational events		
	⊠ None	
testimony		
Support for attending	⊠ None	
meetings and/or travel	Z None	
Patents planned issued or	№	
pending	⊠ None	
Participation on a Data	⊠ None	
•	<b>5</b> 2	
	⊠ None	
committee or advocacy		
Stock of Stock options	⊠ None	
Receipt of equipment,	⊠ None	
services		
Other financial or non-	⊠ None	
financial interests		
ease summarize the above c	onflict of interest in the following box:	
None.		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial interests  Payment for expert  None  None  None  None  None  None  None  None

Date: 2 December 2021				
Your Name:	Nam	Hung Chia		
Manuscript Title: The	Hong	Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review		
and update for 2021				
Manuscript number	if knov	vn): HBSN-21-405		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	⊠ None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame, nest	26 months
2	Curata an acutus eta forma	Time frame: past	36 MONUNS
2	Grants or contracts from	None     Non	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
manuscript writing or educational events  6  Payment for expert testimony  7  Support for attending meetings and/or travel  8  Patents planned, issued or pending  9  Participation on a Data Safety Monitoring Board or Advisory Board	
educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board	
testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
9 Participation on a Data Safety Monitoring Board or Advisory Board  None	
Safety Monitoring Board or Advisory Board	
Safety Monitoring Board or Advisory Board	
· ·	
10   Leadership or fiduciary role	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options None	
12 Receipt of equipment, 🗵 None	
materials, drugs, medical writing, gifts or other	
services	
13 Other financial or non-	
financial interests	
Please summarize the above conflict of interest in the following box:	

Date: 2 December 2	021
Your Name:	_Ada Law
<b>Manuscript Title: Th</b>	e Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 2022	
Manuscript number	(if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
lectures, presentations, speakers bureaus, manuscript writing or educational events   Some serior in the string or education   Some serior in the string or	
manuscript writing or educational events  6  Payment for expert testimony  7  Support for attending meetings and/or travel  8  Patents planned, issued or pending  9  Participation on a Data Safety Monitoring Board or Advisory Board	
educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board  Solve and Safety Monitoring Board or Advisory Board	
testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board	
8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board    None	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  Safety Monitoring Board or	
9 Participation on a Data Safety Monitoring Board or Advisory Board  None	
Safety Monitoring Board or Advisory Board	
Safety Monitoring Board or Advisory Board	
· ·	
10   Leadership or fiduciary role	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options None	
12 Receipt of equipment, 🗵 None	
materials, drugs, medical writing, gifts or other	
services	
13 Other financial or non-	
financial interests	
Please summarize the above conflict of interest in the following box:	

Date: 2 December 2021
Your Name:Dr. Shum Chui Yu Tracy
Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative revie
and update for 2021
Manuscript number (if known): HRSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

_	D		
5	Payment or honoraria for	⊠ None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	⊠ None	
	testimony	None	
	•		
7	Support for attending	⊠ None	
	meetings and/or travel	None	
	,		
8	Patents planned, issued or	⊠ None	
	pending	None	
9	9 Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
		⊠ None	
10	Leadership or fiduciary role	⊠ None	
	in other board, society,	Z None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical		
	writing, gifts or other		
13	Other financial or non	N	
13	Other financial or non- financial interests	⊠ None	
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None.		

Date: 2 December 2021 Your Name: Lam Yim Kwan

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5	Payment or honoraria for		
5	lectures, presentations,	⊠ None	
	speakers bureaus,		
	manuscript writing or		
<i>c</i>	educational events		
6	Payment for expert testimony	⊠ None	
7	Support for attending	⊠ None	
	meetings and/or travel	None	
8	Patents planned, issued or	⊠ None	
	pending		
	Dankining tien and Date		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role	⊠ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
42	D		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	⊠ None	
	services		
13	Other financial or non-	⊠ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None		

Date: 2 December 2021 Your Name: Vince Lau

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	⊠ None	
	provision of study materials,		
	medical writing, article processing charges, etc.)  No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	⊠ None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

5	Payment or honoraria for		
5	lectures, presentations,	⊠ None	
	speakers bureaus,		
	manuscript writing or		
<i>c</i>	educational events		
6	Payment for expert testimony	⊠ None	
7	Support for attending	⊠ None	
	meetings and/or travel	None	
8	Patents planned, issued or	⊠ None	
	pending		
	Dankining tien and Date		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role	⊠ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
42	D		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	⊠ None	
	services		
13	Other financial or non-	⊠ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None		

Date: 2 Decembe	r 2021
Your Name:	Victor Ho Fun LEE
<b>Manuscript Title:</b>	The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 20	021
Manuscript numb	per (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

_	Decimand on heavening for		
5	Payment or honoraria for lectures, presentations,	⊠ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
•	5 5 .	_	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
10		None	
11	Stock or stock options	⊠ None	
10	D 1 1 1 1		
12	Receipt of equipment, materials, drugs, medical	⊠ None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	⊠ None	

# Please summarize the above conflict of interest in the following box:

I declare no conflict of interest pertaining to the work reported in this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2 December	er 2021
Your Name:	CHONG Ching Ning Charing
<b>Manuscript Title</b>	: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 2	021
Manuscript num	ber (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial  None	pranning of the work
1	manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		<b>-</b> : .	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	⊠ None	
	in item #1 above).		
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None	
educational events		
Payment for expert	⊠ None	
testimony		
Support for attending	⊠ None	
meetings and/or travel	Z None	
Patents planned issued or	№	
pending	⊠ None	
Participation on a Data Safety Monitoring Board or	⊠ None	
•	<b>5</b> 2	
in other board, society, committee or advocacy	⊠ None	
Stock of Stock options	⊠ None	
Receipt of equipment, materials, drugs, medical	⊠ None	
services		
Other financial or non- financial interests	⊠ None	
ease summarize the above c	onflict of interest in the following box:	
None.		
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial interests  Payment for expert  None  None  None  None  None  None  None  None

Date: 2 December	r <b>2021</b>
Your Name:	Chung-Ngai Tang
Manuscript Title:	The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review
and update for 20	21
Manuscript numb	per (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	
Time frame: past 36 mo			36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	
4	Consulting fees	⊠ None	

	T					
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None				
	educational events					
6	Payment for expert testimony  Support for attending	None     Non				
7		M N				
,	meetings and/or travel	⊠ None				
8	Patents planned, issued or pending	⊠ None				
	penamb					
9	Participation on a Data	⊠ None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	⊠ None				
	in other board, society, committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	⊠ None				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	⊠ None				
		Notice				
13	Other financial or non- financial interests	⊠ None				
		EN NOTIC				
Ple	Please summarize the above conflict of interest in the following box:					
	None.					
- 1						

Date: 2 December 2021 Your Name: YAU Thomas

Manuscript Title: The Hong Kong Consensus Statements on Unresectable Hepatocellular Carcinoma: Narrative review

and update for 2021

Manuscript number (if known): HBSN-21-405

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	☐ None	Eisai for medical writing			
		Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None	Bayer, Ipsen and Eisai for funding support to			
		□ None				
			investigator-initiated studies			
3	Royalties or licenses	✓ N				
3		⊠ None				
4	Consulting fees					
4	Consulting rees	⊠ None				

			<del>_</del>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None	Bristol Myers Squibb, Eisai, Ipsen, MSD, AstraZeneca,
			Bayer
6	Payment for expert testimony	⊠ None	
7	Support for attending	⊠ None	
	meetings and/or travel		
_			
8	Patents planned, issued or pending	⊠ None	
	pending		
0	5 5 .		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	·		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non- financial interests	⊠ None	

### Please summarize the above conflict of interest in the following box:

TY has received research funding from Bayer, Eisai and Ipsen and speaking honoraria from Bristol Myers Squibb, Eisai, Ipsen, MSD, AstraZeneca, and Bayer.

## Please place an "X" next to the following statement to indicate your agreement: